PCRX - パシラ・ファ―マシュ―ティカルズ （Pacira Pharmaceuticals Inc.） パシラ・ファ―マシュ―ティカルズPCRXのチャート
PCRXの企業情報
| symbol | PCRx |
|---|---|
| 会社名 | Pacira Pharmaceuticals Inc. （パシラ・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 パキラ・ファーマシューティカルズ(Pacira Pharmaceuticals Inc.)は持株会社である。同社は、主に病院と外来手術センターで使用するために、DepoFoam延長放出ドラッグデリバリー技術に基づいて医薬品の開発・製造・商業化に焦点を当てた製薬会社である。主な製品候補EXPOPEL（ブピバカイン・リポソーム注射可能懸濁液）は、DepoFoamにカプセル化されたアミド型局所麻酔薬ブピバカインで構成され、手術部位への単回用量浸潤が示されて術後鎮痛を生じる。EXPOPELの他、DepoFoamは、他の食品医薬品局で承認された商業用製品DepoCyt（e）の基礎でもあり、商業パートナー及び製品候補向けにDepoCyt（e）を生産する。他の製品候補には、DepoMeloxicam（DepoMLX）およびDepoTranexamic Acid（DepoTXA）が含まれる。DepoCyt（e）はリンパ腫性髄膜炎の髄腔内治療に使用される。 パシラ・ファ―マシュ―ティカルズは、米国の持株会社。救急治療者や患者のニ―ズを満たす新薬の臨床治療・商業開発に焦点を当てる。主力製品は、局所鎮痛剤｢EXPAREL｣、リンパ腫性髄膜炎の治療のためDEPOFOAM技術を利用した化学療法剤とシタラビンの徐放性リポソ―ム製剤｢DepoCyt(e)｣などがある。 Pacira BioSciences, Inc.is the industry leader in its commitment to non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. The company's long-acting local analgesic, EXPAREL ® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. In April 2019, Pacira acquired the iovera° system, a handheld cryoanalgesia device used to deliver precise, controlled doses of cold temperature only to targeted nerves. |
| 本社所在地 | 5 Sylvan Way Suite 300 Parsippany NJ 07054 USA |
| 代表者氏名 | David M. Stack David M. Stack |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 973-254-3560 |
| 設立年月日 | 39052 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2011年 |
| 従業員数 | 489人 |
| url | www.pacira.com |
| nasdaq_url | https://www.nasdaq.com/symbol/pcrx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 17.79000 |
| 終値（lastsale） | 45.15 |
| 時価総額（marketcap） | 1849362782.4 |
| 時価総額 | 時価総額（百万ドル） 1925.14 |
| 売上高 | 売上高（百万ドル） 305.12700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1837.407 |
| 当期純利益 | 当期純利益（百万ドル） -11.11800 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Pacira Pharmaceuticals Inc revenues increased 13% to $158.7M. Net loss decreased 80% to $8.1M. Revenues reflect Net product sales increase of 12% to $155M Collaborative licensing and milestone re increase from $336K to $3M. Lower net loss reflects Research and development - Balancing val decrease of 27% to $25M (expense) Product discontinuation decrease of 94% to $252K (expense). |
PCRXのテクニカル分析
PCRXのニュース
Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures 2023/03/29 12:00:00 GlobeNewswire
TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL label to include both single-dose sciatic nerve block in the popliteal fossa as well as femoral nerve block in the adductor canal. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is November 13, 2023.
Pacira Pharmaceuticals PT Lowered to $80 at Barclays 2023/03/03 11:07:01 Investing.com
https://www.investing.com/news/pro/pacira-pharmaceuticals-pt-lowered-to-80-at-barclays-432SI-3021443
Pacira BioSciences, Inc. (PCRX) Q4 2022 Earnings Call Transcript 2023/02/28 17:50:05 Seeking Alpha
Pacira BioSciences, Inc. (NASDAQ:NASDAQ:PCRX) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ETCompany ParticipantsSusan Mesco - Head, Investor RelationsDave Stack - Chairman…
Earnings Preview For Pacira BioSciences 2023/02/27 19:01:43 Benzinga
Pacira BioSciences (NASDAQ: PCRX ) is set to give its latest quarterly earnings report on Tuesday, 2023-02-28. Here''s what investors need to know before the announcement. Analysts estimate that Pacira BioSciences will report an earnings per share (EPS) of $0.83. Pacira BioSciences bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
Pacira to Report 2022 Financial Results on Tuesday February 28, 2023 2023/02/21 13:00:00 GlobeNewswire
TAMPA, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2022 financial results before the open of the U.S. markets on Tuesday, February 28, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.
Pacira BioSciences reports sales of $54.9M for October (NASDAQ:PCRX) 2022/11/14 13:33:13 Seeking Alpha
Pacira BioSciences (PCRX) has reported prelim net product sales of $54.9M for October 2022. EXPAREL net product sales were $45M, compared with $42.5M for October 2021, with average…
Pacira BioSciences, Inc. (PCRX) Q3 2022 Earnings Call Transcript 2022/11/03 18:36:03 Seeking Alpha
Pacira BioSciences, Inc. (NASDAQ:NASDAQ:PCRX) Q3 2022 Earnings Conference Call November 03, 2022 08:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack -…
Assessing Pacira BioSciences’ Growth Prospects (NASDAQ:PCRX) 2022/10/20 17:00:55 Seeking Alpha
Pacira stock looks well-positioned to deliver shareholder value in the following years despite some of the near-term challenges and headwinds. Click here to see why PCRX is a buy.